Biosplice Therapeutics
Biosplice Therapeutics is a biopharmaceutical company focused on developing therapies that modulate alternative splicing, with a clinical pipeline targeting osteoarthritis, oncology, and neurological disorders.
Services
Biosplice Therapeutics focuses on delivering first-in-class therapies that harness alternative splicing. The company aims to produce biological insights and unique chemical equity that deliver therapeutic modulation of alternative splicing by targeting the CLK/DYRK family kinases. The therapeutic modulation aims to address areas of significant unmet medical need such as osteoarthritis, oncology, neurology, and other medical conditions.
Clinical Pipeline
Biosplice Therapeutics has a diverse clinical pipeline that primarily targets osteoarthritis and oncology. The pipeline includes early-stage programs in neurology and other areas where there is a significant unmet medical need. The company has designed a range of new chemical entities that selectively bind to specific members of the CLK/DYRK family, aimed at providing effective therapeutic solutions. These entities are amenable to both local and systemic administration, including CNS exposure.
Therapeutic Modulation of Alternative Splicing
Biosplice Therapeutics has established clinical proof-of-concept for therapeutic modulation of alternative splicing with the development of lorecivivint. This drug specifically targets osteoarthritic disease progression, showing the potential of modulating alternative splicing for therapeutic benefits. Additionally, clinical trials in oncology focus on pan-CLK and DYRK inhibition, aiming to achieve similar therapeutic splicing modulation.
Chemical Entities and Drug Development
Biosplice Therapeutics has developed a compendium of new chemical entities designed to selectively bind to specific members of the CLK/DYRK family of kinases. These chemical entities are suitable for local or systemic administration and are capable of crossing the blood-brain barrier to reach CNS targets. The aim is to provide new therapeutic options for diseases with currently limited treatments.